Why the study?
Do vasodilators, particularly ACE inhibitors, reduce mortality and morbidity in patients with heart failure or left ventricular dysfunction?
Do vasodilators, particularly ACE inhibitors, reduce mortality and morbidity in patients with heart failure or left ventricular dysfunction?
ACE inhibitors protect the myocardium and improve clinical outcomes in patients with impaired systolic ventricular function by attenuating ventricular remodeling.
No takes yet. Share an insight, caveat, or question.
Supports ACE inhibitor use in HFrEF; leaves open optimal sequencing with ARNI/SGLT2i in contemporary cohorts.
James B. Young (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: